Dermatologydrug survivaldupilumab
Sustained Efficacy and Safety of Dupilumab in Children with Moderate to Severe Atopic Dermatitis: Insights from a 3-Year Dutch Cohort Study
By MedXY|Oct 2, 2026
This study highlights dupilumab’s long-term effectiveness and safety in managing pediatric atopic dermatitis over 3 years, revealing age-related differences in symptom control and treatment persistence.